Treatment for autoimmune conditions continue to see significant Medicare program changes during the COVID-19 pandemic. Current shifts and flexibilities attempt to mitigate the interruptions in care through providing solutions that balance safety and access to necessary treatment. However, these health system disruptions resulting from COVID-19 are significantly reshaping how patients receive care. Unanticipated changes in utilization, such as a large shift from provider-administered to self-administered drugs, will impact coverage, utilization management, and health plan costs. Additionally, there are clinical challenges that must be closely considered by patients and physicians for transition to a new therapy. All healthcare stakeholders will need to understand the immediate and future effects of these changes.

Key topics included:

• Policy shifts during COVID-19
• Current status of Medicare Part B and D
• Provider and patient access and impact
• Future state of the Medicare B and D benefits
• Coverage and cost implications